Prevention And Private-Public Partnerships Lie At The Heart Of China’s Latest Health Care Initiative
This article was originally published in Clinica
Against the backdrop of a fast-aging population and dwindling labor force, China is facing increasing cases of chronic disease and cancer, which is sparking a budget shortfall for basic insurance funds. The solution, it hopes, lies in engaging private players and stressing preventive care.
You may also be interested in...
Podcast: Living In China's Coronavirus Lockdown; Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.